Jeanmarie Guenot’s Historic Career Achievements

JeanMarie Guenot is the president of Amphivena Therapeutics Inc, located in San Francisco. The company specializes in the development of cancer treatment immune therapies. She has over 20 years experience as a business administrator, which makes her a great leader. She has served in both the public and the private sector. She deals with venture capital, project management, commercial development, and pharmaceuticals R&D. Through Guenot LLC, she offers consultation services such as licensing, acquisitions, project management, commercial planning, mergers, alliance, and finance management to both pharmaceutical and biotechnology companies.

Guenot specializes in X-ray, semi-empirical and mechanical methods, and drug design. She trained in medicinal and physical chemistry dealing with protein structure, refinement, and NMR. JeanMarie Guenot holds a Ph.D. from the University of California and an MBA from the University of Pennsylvania.

She started her scientific career at Hoffmann-La Roche working as the principal scientist in preclinical R&D. At the firm, she developed drugs for inflammation, autoimmune diseases, metabolic diseases, and oncology.

The business career started at Atlas Ventures as a manager of venture capital investments. She created the life of science companies while in the field. Before becoming the president of Amphivena Therapeutics, she served in different roles on LinkedIn. JeanMarie served as the vice president of business and corporate development at PDL BioPharma where she facilitated licensing, acquisitions, mergers and alliance management of commercial product portfolios.

In addition, Jeanmarie Guenot championed the PDL and Hoffmann-La Roche deal. The deal involved a 50:50 collaboration in commercialization and development of their drugs. For her efforts, she was awarded BioBusiness Network Innovative Bio-Partnering Award in 2005. She also received a Deal of Distinction from Licensing Executive Society in 2006.

JeanMarie Guenot is an experienced leader and manager of large companies. It is through her hard work and professional skills that she achieved success. JeanMarie conducts her duties with integrity, and she has made significant contributions to the success of Amphivena Therapeutics.

Amphivena Therapeutics was founded in 2012. In 2015, the company raised $9.7 million and had a committed and hardworking staff. The main aim of the company is to eradicate blood cancers by harnessing autoimmune system to destroy the tumor cells.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

Deadly Sites

Hi, guest!